Drug intelligence / Profile preview

EB051

Development stage: Unknown
Lead developer: Beijing Dongfang Baitai Biotechnology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

EB051 is a recombinant humanized monoclonal antibody that targets the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), an immune checkpoint molecule. Developed by Beijing Dongfang Baitai Biotechnology, EB051 is designed to enhance the body's immune response against cancer cells by inhibiting the interaction between CTLA-4 and its ligands, CD80 (B7-1) and CD86 (B7-2). This blockade prevents the inhibitory signaling that normally suppresses T-cell activity, thereby promoting T-cell activation, proliferation, and enhanced anti-tumor immune responses. EB051 is currently being evaluated in Phase 1 clinical trials for the treatment of advanced solid tumors.

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)

Beyond the preview

Go deeper on EB051.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EB051.

Explore the full profile